<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00505167</url>
  </required_header>
  <id_info>
    <org_study_id>0910-0459</org_study_id>
    <nct_id>NCT00505167</nct_id>
  </id_info>
  <brief_title>Memantine Versus Donepezil in Early Stages of Alzheimer's Disease</brief_title>
  <official_title>Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Miguel Servet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinica Quiron de Zaragoza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de Zaragoza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Barbastro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Royo Villanova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Miguel Servet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well known that in the brain of the patients with Alzheimer's disease there is a
      glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity
      antagonist of NMDA glutamate receptors. The use of this drug in the early phases of the
      disease could provide neuroprotective effects and delay of progression. The effects of
      memantine should be compared to those of donepezil, which is the most prescribed
      anticholinesterase drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On the basis of the excess of glutamatergic stimulation, our objective is to demonstrate
      whether memantine could have a neuroprotective effect in Alzheimer's disease when
      administered in the early stages and in comparison to donepezil. The patients would be
      randomized to receive one of these drugs. At baseline we would evaluate the patients from a
      clinical standpoint with the ADAS-cog, the neuropsychiatric Inventory and a scale of daily
      living activities.We also would carry out Magnetic Resonance Spectroscopy in several areas of
      the brain (medial temporal lobe, prefrontal region, cingulate gyrus and occipital lobe) so as
      to measure the concentration of N-acetyl-aspartate which is a marker of neuronal density.Then
      we treat the patients with either memantine or denepezil and after 6 months we would repeat
      the same procedures as we did at baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the Levels of the metabolite N-acetyl-aspartate in several areas of the brain.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the clinical scales observed after treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Dementia, Alzheimer Type</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to receive memantine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to receive donepezil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Patients randomized to receive either memantine or donepezil</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ebixa (Memantine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Patients randomized to receive either memantine or donepezil</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Aricept (Donepezil)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical criteria of probable Alzheimer's disease in the stages mild-to-moderate with
             a Mini-Mental score higher than 15 points.

        Exclusion Criteria:

          -  Previous treatment with anticholinesterase drugs or memantine.

          -  Advanced stages of the disease

          -  Lack of a reliable caregiver.

          -  Dementias other than Alzheimer's disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro J Modrego, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology. Hospital Miguel Servet. Zaragoza. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Barbastro</name>
      <address>
        <city>Barbastro</city>
        <state>Huesca</state>
        <zip>50508</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cenro de especialidades San Jos√©. Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Royo Villanova</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2007</study_first_posted>
  <last_update_submitted>December 26, 2008</last_update_submitted>
  <last_update_submitted_qc>December 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Pedro J Modrego</name_title>
    <organization>Department of Neurology. hospital Miguel Servet. Zaragoza. Spain</organization>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Memantine</keyword>
  <keyword>Donepezil</keyword>
  <keyword>Magnetic resonance Spectroscopy</keyword>
  <keyword>randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

